tradingkey.logo
搜尋

STAAR Surgical Co

STAA
添加自選
27.790USD
-0.360-1.28%
收盤 07/02, 13:00美東報價延遲15分鐘
1.38B總市值
虧損本益比TTM

STAAR Surgical Co

27.790
-0.360-1.28%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.28%

5天

-5.12%

1月

-6.93%

6月

+17.75%

今年開始到現在

+20.36%

1年

+55.60%

關鍵數據
28.350今開
28.590最高
508.77K成交量
虧損本益比TTM
55.94本益比動
--股利TTM
1.02%換手率
28.150昨收
27.465最低
11.73M成交額
虧損本益比靜
3.93市淨率
0.00%股息率 TTM
-4.63%ROA
30.81052週最高
1.15量比
-20.21M淨利潤
49.78M總股本
-0.4200每股盈餘TTM
1.02Beta
-5.99%ROE
14.69052週最低
4.00%振幅
73.63%毛利率
1.38B總市值
-1.87回報/風險
3.07%風險率

TradingKey STAAR Surgical Co股票評分

單位: USD 更新時間: 2026-07-02

操作建議

STAAR Surgical Co當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名78/204位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為29.67。中期看,股價處於上升通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

STAAR Surgical Co評分

相關信息

行業排名
78 / 204
全市場排名
184 / 4565
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

STAAR Surgical Co亮點

亮點風險
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
估值低估
公司最新PE估值-66.16,處於3年歷史低位
機構減倉
最新機構持股58.06M股,環比減少15.41%
保羅都鐸瓊斯持倉
明星投資者保羅都鐸瓊斯持倉,最新持倉31.04K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.45

分析師目標

基於 11 分析師
持有
評級
29.667
目標均價
+5.39%
漲幅空間

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

STAAR Surgical Co簡介

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
公司代碼STAA
公司STAAR Surgical Co
CEOFarrell (Stephen C)
網址https://www.staar.com/

常見問題

STAAR Surgical Co(STAA)的當前股價是多少?

STAAR Surgical Co(STAA)的當前股價是 27.79。

STAAR Surgical Co 的股票代碼是什麼?

STAAR Surgical Co的股票代碼是STAA。

STAAR Surgical Co股票的52週最高點是多少?

STAAR Surgical Co股票的52週最高點是30.81。

STAAR Surgical Co股票的52週最低點是多少?

STAAR Surgical Co股票的52週最低點是14.69。

STAAR Surgical Co的市值是多少?

STAAR Surgical Co的市值是1.37B。

現在STAAR Surgical Co(STAA)的股票是買入、持有還是賣出?

根據分析師評級,STAAR Surgical Co(STAA)的總體評級為signal_hold,目標價格為29.67。

STAAR Surgical Co(STAA)股票的每股收益(EPS TTM)是多少

STAAR Surgical Co(STAA)股票的每股收益(EPS TTM)是-1.62。